News from oncoinvent as A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

26 Feb, 2019, 07:50 GMT Oncoinvent Awarded 4,6 MNOK in Innovation Funding

Oncoinvent is pleased to announce that the Oslo University Hospital and Oncoinvent have each been awarded Innovation Funding to develop Radspherin®...


19 Feb, 2019, 07:58 GMT Oncoinvent Receives Manufacturing Authorization for Clinical Trial Material

Oncoinvent is pleased to announce that it has received a manufacturing authorization (GMP certificate) for production of Radspherin® clinical trial...


15 Feb, 2019, 08:30 GMT Oncoinvent Signs Distribution Agreement With Radiopharmaceutical Wholesaler

ncoinvent has signed an agreement with the Institute of Energy Technology (IFE) for the distribution of Radspherin (investigational medicinal...


01 Feb, 2019, 13:01 GMT Oncoinvent Announces Appointment of New Chief Financial Officer

Oncoinvent is pleased to announce it has appointed Tore Kvam as Chief Financial Officer. Mr. Kvam has a extensive experience as CFO with several...


12 Oct, 2018, 14:19 BST Oncoinvent to Present and Attend the 32nd Annual Congress of the European Association of Nuclear Medicine

Oncoinvent announces that Radspherin® research findings will be presented at the 32nd Annual Congress of the European Association of Nuclear Medicine ...


28 Jun, 2018, 11:11 BST Oncoinvent Researcher Pesents Findings at SNMMI Annual Meeting in Philadelphia

Oncoinvent is pleased to announce that research scientist Elisa Napoli presented Radspherin® research findings earlier this week during the Monday...


13 Apr, 2018, 15:09 BST Oncoinvent Sets Regulatory Strategy for Development of Radspherin ®

Oncoinvent announced today that the regulatory strategy that will be used in the development of its lead product Radspherin® has been selected. The...


05 Apr, 2018, 10:58 BST Oncoinvent Publishes Data Explaining Radspherin ® 's Mechanism of Action

Data describing and explaining Radspherin® 's mechanism of action has been published in the Journal of Labelled Compounds and Radiopharmaceuticals....


13 Dec, 2017, 17:02 GMT Opening of the Radspherin® Production and Laboratory Facility

Oncoinvent held an opening ceremony for its new production and lab facilities today. A total of 40 guests attended the opening. The new production...


15 Nov, 2017, 15:28 GMT Radspherin® EU patent and OI-3 antibody US patent issued

Oncoinvent announced today that European Patent 3111959 entitled "Radiotherapeutic particles and suspensions" has issued. The patent relates to a...


16 May, 2017, 06:07 BST Oncoinvent: A Novel Method for Making 212 Pb-labeled Monoclonal Antibodies Using a Novel 224 Ra-based Generator Solution

Oncoinvent researchers collaborate to develop a system to generate alpha-particle releasing radioimmunoconjugates that may be simpler and less...


12 May, 2017, 12:38 BST Oncoinvent Strengthens Management and Research Teams

Key positions to assist in the development and commercialization of Radspherin® have been filled, bringing valuable expertise and experience to the...


09 Feb, 2017, 08:49 GMT Oncoinvent Closes $ 25 Million Private Placement

Financing will support development of Radspherin™, a novel radiotherapeutic treatment for peritoneal carcinomatosis Oncoinvent announced today the...